LabCompass

Prasad Kopparapu

Medicine · Indiana University

Mid career · publishing since 2010Rising activity

Publications

98

Citations

618

Est. group size

Recurring co-author estimate

Active years

16

Publishing since 2010

Research summary
AI-generated

Prasad Kopparapu conducts medical research focused on lung cancer, particularly small-cell lung cancer, using approaches such as analysis of cell-free DNA (genetic material shed by tumors into the blood) and DNA methylation to classify cancer subtypes. The work also includes developing and characterizing small-molecule drug candidates, such as compounds targeting the Bcl-2 protein involved in cancer cell survival and metastasis.

Small-cell lung cancerCell-free (circulating) tumor DNACancer genomics and DNA methylationSmall-molecule cancer therapeuticsBcl-2 and breast cancer metastasis

Publication activity was low and intermittent in the late 2010s but rose sharply from 2023 onward, indicating a recent period of high output.

Generated by claude-opus-4-8 from public bibliographic data · Jul 9, 2026

In context
Among 4,618 mid career Medicine PIs within our index
Citations: 618cohort median 616
h-index: 11cohort median 11
Publications / year (recent): 16.8cohort median 3.4

Typically publishes in teams of ~15 · 0% small-team papers (≤3 authors) · across 14 venues

Publication cadence
Publications per year over the last 10 years — averaging 16.8/year recently
172018: 2 publications18192020: 5 publications202021: 1 publication212022: 4 publications222023: 47 publications47232024: 23 publications242025: 10 publications2526
Recent publications
Publishes in
  • Genetics in Medicine Open×5
  • Cancer Research×4
  • Clinical Cancer Research×2
  • JTO Clinical and Research Reports×2
  • Cancer Cell×1
Similar researchers
By research-topic overlap

This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.

Last updated Jul 27, 2026.

Claim or correct this profile